Cochlear Limited (ASX: COH) - Share Price
Current share price for COH : $118.030 1.48 (1.27%)+
Cochlear Limited (COH), an ASX-listed company, has been the global leader in implantable hearing solutions for over 40 years, providing a range of implants and sound processor upgrades that deliver a lifetime of hearing outcomes.
COH General Information +
| ASX Code | COH |
| Website | N/A |
| Industry/Sector | Health Care Equipment |
| Market Cap ($M) | 7,719 |
| COH Share Price | $118.030 |
| Day High | $118.760 |
| Day Low | $115.640 |
| Last Close | $116.550 |
| COH Share Price Movement | $1.48 ( 1.27% ) |
Prices as at 16:40, 26 Jun 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Cochlear Limited (COH) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|---|---|---|---|---|---|---|
| Result | $2.15 | 85% | 19 Mar 2026 | 13 Apr 2026 | - | - | - |
| HFResult | $2.15 | 85% | 18 Sep 2025 | 13 Oct 2025 | - | - | - |
| Result | $2.15 | 80% | 20 Mar 2025 | 14 Apr 2025 | - | - | - |
See all dividends from Cochlear Limited (COH) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Cochlear Limited (COH) price-sensitive announcements
COH - Trading update and reduction to FY26 earnings guidance
Cochlear Limited has issued a trading update and revised its FY26 earnings guidance downwa
Cochlear Limited (COH)
22 Apr 2026 | 8:20 AM
22 Apr 2026 | 8:20 AM
COH - HY26 Result - Presentation Slides
Cochlear Limited's HY26 Result Presentation highlights financial performance, strategic pr
Cochlear Limited (COH)
13 Feb 2026 | 7:34 AM
13 Feb 2026 | 7:34 AM
COH - HY26 Result - ASX & Media Release
Cochlear Limited reported their financial results for the half-year ending December 2025,
Cochlear Limited (COH)
13 Feb 2026 | 7:33 AM
13 Feb 2026 | 7:33 AM
COH - Appendix 4D and Half Year Financial Report
Cochlear Limited's interim financial report for the half year ended 31 December 2025 shows
Cochlear Limited (COH)
13 Feb 2026 | 7:32 AM
13 Feb 2026 | 7:32 AM
Cochlear Limited (COH) Recent ASX Announcements
COH Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2026F | $462.53 | $701.75 | 10.90% | 43.96 | 490.00 | 1.59% | 100.0% |
| 2025F | $417.22 | $633.00 | 7.60% | 48.74 | 440.00 | 1.43% | 100.0% |
| 2024A | $386.60 | $588.25 | 27.00% | 48.98 | 410.00 | 1.42% | 75.1% |
COH Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2024 A | 2025 F | 2026 F | 2024 A | 2025 F | 2026 F | 2024 A | 2025 F | 2026 F | ||
| Cochlear Limited (COH) | $7,622M | 0.0171 | -0.1883 | 0.0862 | 19.4760 | 23.9938 | 22.0906 | 3.69% | 2.97% | 3.17% |
| Fisher & Paykel Healthcare Corporation Limited (FPH) | $18,517M | 0.1388 | 0.1359 | 0.1882 | 47.6788 | 41.9728 | 35.3238 | 1.38% | 1.47% | 1.66% |
| ResMed Inc. (RMD) | $16,678M | 0.3087 | 9.7634 | 0.0805 | 200.8253 | 18.6581 | 17.2679 | 1.15% | 1.20% | 1.27% |
COH Directors
| Name | Position | Start Date |
|---|---|---|
| Ms Christine Frances McLoughlin | Non-Executive Director | 1 Nov 2020 |
| Sir Michael Grenfell Daniell | Non-Executive Director | 1 Jan 2020 |
| Ms Karen Lee Collett Penrose | Non-Executive Director | 1 Jul 2022 |
| Mr Richard John Freudenstein | Non-Executive Director | 25 Aug 2025 |
| Professor Bruce Gregory Robinson AC | Non-Executive Director | 13 Dec 2016 |
| Mr Michael del Prado | Non-Executive Director | 1 Jan 2022 |
| Ms Caroline Louise Clarke | Non-Executive Director | 2 Sep 2024 |
| Ms Catriona Alison Deans | Non-Executive Director, Non-Executive Chairman | 1 Jan 2015 |
| Mr Dig Howitt | President, Chief Executive Officer, Managing Director | 14 Nov 2017 |
Cochlear Limited (COH) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 19 Feb 2026 | ROBINSON AC, Bruce | Buy | Indirect Shares | 253 | $198.220 | $50,149.660 |
| 18 Feb 2026 | PENROSE, Karen | Buy | Indirect Shares | 100 | $201.220 | $20,122.000 |
| 16 Feb 2026 | FREUDENSTEIN, Richard | Buy | Indirect Shares | 485 | $203.609 | $98,750.170 |
See all changes in directors' interest & trades for Cochlear Limited (COH) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
COH Management
| Name | Position |
|---|---|
| Dr Sarah Thom | Chief Financial Officer |
| Karen O'Driscoll | Chief Information Officer |
| Jan Janssen | Chief Technology Officer |
| Kristy Jo | Company Secretary |
| Rob McGrory | Company Secretary |
| Rob McGrory | Group General Counsel & Company Secretary |
| Stu Sayers | President, Asia Pacific & Latin America |
| Anthony Bishop | President, Europe, Middle East and Africa (EMEA) |
| Lisa Aubert | President, North America |
| Brian Kaplan | Senior Vice President, Global Clinical Strategy and Innovation |
| Jennifer Hornery | Senior Vice President, Global People & Culture |
| Dean Phizacklea | Senior Vice President, Global Strategic Marketing |
| Greg Bodkin | Senior Vice President, Global Supply Chain |
COH Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Cochlear Limited (COH). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 4,836,294 (7.40%) | State Street Corporation and subsidiaries |
| 4,300,283 (6.60%) | BlackRock, Inc |
| 3,756,745 (5.70%) | The Vanguard Group,Inc |
COH Calendar of Events
| Date | Event |
|---|---|
| 12 February 2027 | Report (Interim) |
| 14 August 2026 | Report (Annual) |
| 14 August 2026 | Report (Prelim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
